Sol-Gel Technologies: Drops after delay in FDA review of skin cream

SOL-GEL TECHNOLOGIES

27/04/2021 16:00

** Shares of skin disease drug developer  SLGL.O  fall 21.4%
to $10.80
    ** FDA says action on SLGL's marketing application for its
epsolay topical cream could not be taken as a pre-approval
inspection of the drug's production site has not been conducted
yet  urn:newsml:reuters.com:*:nGNX3KKtmb
    ** Epsolay is intended for the treatment of rosacea, a
condition causing reddened skin and pimples, usually affecting
the face
    ** The agency had set a target action date for the drug of
April 26 - SLGL
    ** SLGL had risen 40.4% YTD, as of last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))